Table 4.
Meta-regression analysis using study-level characteristics in relation to 1-year PFS rate in ASCT-ineligible studies
| Variable | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| Coefficient | Standard error | 95% CI | p-value | Coefficient | Standard error | 95% CI | p-value | |
| Stage III/IV (%) | −0.0033 | 0.0022 | −0.0075 to 0.0009 | 0.126 | NA | NA | NA | NA |
|
| ||||||||
| Prior ASCT (%) | −0.0014 | 0.0015 | −0.0044 to 0.0016 | 0.349 | NA | NA | NA | NA |
|
| ||||||||
| Refractory to last treatment (%) | −0.0001 | 0.0011 | −0.0021 to 0.002 | 0.939 | NA | NA | NA | NA |
|
| ||||||||
| Median previous lines of treatment | −0.0352 | 0.0209 | −0.0761 to 0.0057 | 0.092 | −0.0421 | 0.0184 | −0.0782 to −0.006 | 0.022 |
|
| ||||||||
| Complete remission (%) | 0.0061 | 0.0008 | 0.0045 to 0.0076 < 0.001 | NA | NA | NA | NA | |
|
| ||||||||
| Regimens | < 0.001 | |||||||
|
| ||||||||
| CAR T-cell therapy (reference) | NA | NA | NA | NA | NA | NA | NA | NA |
|
| ||||||||
| Chemotherapy | −0.158 | 0.0571 | −0.27 to −0.0461 0.006 | −0.2081 | 0.0578 | −0.3214 to −0.0947 | < 0.001 | |
|
| ||||||||
| Ibrutinib-based therapy | −0.1627 | 0.0855 | −0.3304 to 0.005 | 0.057 | −0.1635 | 0.0814 | −0.323 to −0.004 | 0.045 |
|
| ||||||||
| Lenalidomide-based therapy | −0.121 | 0.0772 | −0.2723 to 0.0304 | 0.117 | −0.1483 | 0.074 | −0.2934 to −0.0032 | 0.045 |
|
| ||||||||
| Loncastuximab | −0.1346 | 0.1131 | −0.3562 to 0.0869 | 0.234 | −0.1356 | 0.106 | −0.3434 to 0.0722 | 0.201 |
|
| ||||||||
| Polatuzumab-BR | −0.033 | 0.0775 | −0.1849 to 0.1189 | 0.670 | −0.0674 | 0.0749 | −0.2141 to 0.0794 | 0.368 |
|
| ||||||||
| Selinexor | −0.1806 | 0.113 | −0.4022 to 0.0409 | 0.110 | −0.2237 | 0.1076 | −0.4345 to −0.0128 | 0.038 |
|
| ||||||||
| Tafasitamab | 0.0607 | 0.0967 | −0.1289 to 0.2503 | 0.530 | 0.0184 | 0.0937 | −0.1652 to 0.202 | 0.844 |
|
| ||||||||
| Other | −0.2321 | 0.0557 | −0.3414 to −0.1229 | < 0.001 | −0.2486 | 0.053 | −0.3525 to −0.1447 | < 0.001 |
ASCT, autologous stem cell transplantation; BR, bendamustine and rituximab; CAR, chimeric antigen receptor; CI, confidence interval; NA, not available; PFS, progression-free survival.